Novomix 30 Flexpen (Insulin Aspart)

Insulin aspart, the active ingredient in Novomix 30 Flexpen, is an insulin analog presented as a strength/form for subcutaneous use. It treats diabetes mellitus by regulating blood glucose levels in adults and children. GNH USA supplies Novomix 30 Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Novomix 30 Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novomix 30 Flexpen is an insulin analog that acts on the glucose regulation pathway in diabetes mellitus. - Type 1 diabetes mellitus: improves basal and prandial glucose control. - Type 2 diabetes mellitus: provides mealtime insulin coverage alongside basal insulin. - Gestational diabetes mellitus: assists in achieving target blood glucose levels during pregnancy.

Insulin aspart may cause adverse reactions ranging from mild to serious.

Common Side Effects: - Hypoglycaemia: low blood glucose levels. - Injection site reactions: redness, swelling, or itching. - Lipodystrophy: localized changes in fat tissue. - Weight gain: increase in body weight.

Serious or Rare Side Effects: - Severe hypoglycaemia with loss of consciousness. - Allergic reactions including anaphylaxis. - Edema: abnormal swelling. - Vision changes: blurred blur ​   ​  ​  ​  ​  ​  ​  ​  ​

Novomix 30 Flexpen should be used  g      ​  ​  …  … … … … … … … … … … … … … … … … …  t  ​   … … … … … … … … … … … … … … … … … … … … …

-       ...  … … … … … … … … … … … … … … … … … … … - … … … … … …  … … … … … … … … … … """""